<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03241810</url>
  </required_header>
  <id_info>
    <org_study_id>MM-121-02-02-10</org_study_id>
    <secondary_id>2017-000565-76</secondary_id>
    <nct_id>NCT03241810</nct_id>
  </id_info>
  <brief_title>Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer</brief_title>
  <acronym>SHERBOC</acronym>
  <official_title>SHERBOC: A Double-blind, Placebo-controlled, Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Hormone Receptor-positive, Heregulin Positive (HRG+), HER2 Negative Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merrimack Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merrimack Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multi-center, randomized, double-blind, placebo-controlled, Phase 2 study in
      postmenopausal women with heregulin positive, hormone receptor positive, HER2 negative
      metastatic, unresectable breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, double-blind, placebo-controlled international phase 2 trial in
      patients with HRG+, HR+, HER2- metastatic breast cancer that has progressed following
      treatment with no more than 2 prior therapies, one of which must have been a CDK inhibitor.
      All patients will be screened for heregulin using central testing, and eligible patients will
      be randomized to receive either seribantumab + fulvestrant or placebo + fulvestrant. Disease
      status will be assessed according to RECIST v 1.1 to support the primary endpoint.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 15, 2017</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized in a 1:1 ratio (experimental arm versus active comparator arm) using an Interactive Web Response System (IWRS). Randomization will be stratified based on bone-only disease (yes, no) and geographic region (US, non-US).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>This is a multi-center, randomized, double-blind, placebo-controlled Phase 2 Study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>A total study duration of approximately 20 months is expected. The primary analysis will be initiated when 58 PFS events have occurred</time_frame>
    <description>Time from randomization to disease progression according to RECIST v 1.1 as assessed by the Investigator</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>A total study duration of approximately 20 months is expected.</time_frame>
    <description>Time from randomization to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>A total study duration of approximately 20 months is expected.</time_frame>
    <description>Based on RECIST v 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>A total study duration of approximately 20 months is expected.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of treatment-emergent adverse events reported with the combinations of seribantumab plus fulvestrant versus fulvestrant alone</measure>
    <time_frame>A total study duration of approximately 20 months is expected.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) profile of seribantumab when given in combination with fulvestrant and of fulvestrant when given in combination with serbantumab.</measure>
    <time_frame>A total study duration of approximately 20 months is expected.</time_frame>
    <description>Pharmacokinetic (PK) evaluation will be performed on samples obtained pre-dose on day 1 and 15 of each 28-day cycle to assess pre-treatment trough concentrations of MM-121. The maximum observed concentration (Cmax) will be presented and will be calculated usig Non-compartmental analysis (NCA). Serum levels of MM-121 will be measured at a central lab using an enzyme-linked immunosorbent assay (ELISA).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Seribantumab
Fulvestrant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo
Fulvestrant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seribantumab</intervention_name>
    <description>Seribantumab is a human monoclonal antibody that targets ErbB3, a cell surface receptor that is activated by the ligand heregulin. Heregulin-driven ErbB3 signaling has been implicated as a mechanism of tumor growth and resistance to targeted, cytotoxic and anti-endocrine therapies. When used in the combination setting, seribantumab is designed to block ErbB3 signaling in order to enhance the anti-tumor effect of a combination therapy partner.</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>MM-121</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>Fulvestrant is a drug treatment of hormone receptor-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor.</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Faslodex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        To be eligible for participation in the study, patients must meet the following criteria.
        Patients who are HRG negative do not need to complete screening procedures beyond HRG
        assessment.

          1. Patients must have histologically or cytologically confirmed ER+ and/or PR+ (with
             staining of &gt;1% cells) breast cancer.

          2. Patients with confirmed postmenopausal status due to either surgical/natural menopause
             or ovarian suppression.

          3. Patients must be HER2 negative.

          4. Patient must have at least one lesion amenable to either core needle biopsy or fine
             needle aspiration.

          5. Patient must have a positive in-situ hybridization (ISH) test for heregulin, as
             determined by centralized testing of unstained tumor tissue.

          6. Patients that have progressed following at least one but no more than two prior
             systemic therapies in the locally advanced or metastatic disease setting.

          7. Patients with documented progression of locally advanced or metastatic disease as
             defined by RECISTv1.1 (Exception: patients with bone-only metastatic disease are
             eligible if they have at least 2 lytic lesions visible on a CT or MRI and have
             documented disease progression on prior therapy based on the appearance of new
             lesions).

          8. Patients with bone-only lesions who have received radiation to those lesions must have
             documented progression following radiation therapy.

          9. ECOG Performance Score (PS) of 0 or 1.

         10. Patients with adequate bone marrow reserves.

         11. Adequate hepatic function.

         12. Adequate renal function.

         13. Patient has recovered from clinically significant effects of any prior, surgery,
             radiosurgery, or other antineoplastic therapy.

         14. Patients who have experienced a venous thromboembolic event within 60 days of signing
             the main consent form should have been treated with anti-coagulants for at least 7
             days prior to beginning treatment and for the duration of treatment on this study.

        Exclusion Criteria:

        Patients must meet all the inclusion criteria listed above and none of the following
        exclusion criteria.

          1. Prior treatment with an anti-ErbB3 antibody.

          2. Prior treatment with a chemotherapy in the locally advanced or metastatic disease
             setting.

          3. Patients cannot have received prior treatment with fulvestrant or other SERDs in the
             locally advanced or metastatic setting.

          4. Uncontrolled CNS disease or presence of leptomeningeal disease.

          5. Inflammatory breast cancer.

          6. History of another active malignancy that required systemic therapy in the last 2
             years. Patients with prior history of in-situ cancer, basal, or squamous cell skin
             cancer are eligible.

          7. Patients with an active infection, or unexplained fever &gt; 38.5 C during screening
             visits or on the first scheduled day of dosing, which in the investigator's opinion
             might compromise the patients participation in the trial or affect the study outcome.
             At the discretion of the investigator, patients with tumor fever may be enrolled.

          8. Known hypersensitivity to any of the components of seribantumab, fulvestrant, or who
             have had hypersensitivity reactions to fully human monoclonal antibodies.

          9. NYHA Class III or IV congestive heart failure.

         10. Patients with a significant history of cardiac disease (i.e. uncontrolled blood
             pressure, unstable angina, myocardial infarction within 1 year or ventricular
             arrhythmias requiring medication) are also excluded.

         11. Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals; or active
             human immunodeficiency virus (HIV) infection, active hepatitis B infection or active
             hepatitis C infection.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Confirmed postmenopausal status due to either surgical/natural menopause or ovarian suppression (initiated at least 28 days prior to Day 1 of Cycle 1).</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tiffany Crowell</last_name>
    <phone>617-441-1000</phone>
    <email>tcrowell@merrimack.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marc Pipas, MD</last_name>
    <phone>617-441-1000</phone>
    <email>mpipas@merrimack.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ironwood Cancer and Research Centers- Chandler</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kari James</last_name>
      <email>kjames@ironwoodcrc.com</email>
    </contact>
    <contact_backup>
      <last_name>Ciria Luevano</last_name>
      <email>cluevano@ironwoodcrc.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Highland Oncology Group</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Bailey</last_name>
      <email>ABailey@hogonc.com</email>
    </contact>
    <contact_backup>
      <last_name>Mary Carriker</last_name>
      <email>MCarriker@hogonc.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Beverly Hills Cancer Center</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90404-2131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lennea Chap, MD</last_name>
      <email>LCHap@BHCancerCenter.com</email>
    </contact>
    <contact_backup>
      <last_name>Francisco Capilla</last_name>
      <email>FCapilla@BHCancerCenter.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Annabel Castaneda</last_name>
      <email>annabelc@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Naisargee Shah</last_name>
      <email>naisargee.shah@stanford.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Saint Helena Hospital</name>
      <address>
        <city>Saint Helena</city>
        <state>California</state>
        <zip>94574</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wahu Osseso</last_name>
      <email>osesow@ah.org</email>
    </contact>
    <contact_backup>
      <last_name>Shalese Canby</last_name>
      <email>shalese.canby@ah.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Goodman</last_name>
      <email>dgoodman@med.miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>Yisseny Delgado</last_name>
      <email>yisenny.delgado@med.miami.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UF Health Cancer Center at Orlando Health</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leticia Morales</last_name>
      <email>leticia.morales@orlandohealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Pelley</last_name>
      <email>jennifer.pelley@orlandohealth.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvonne Gorham</last_name>
      <email>yvonne.gorham@moffitt.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbus Regional Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Alexander</last_name>
      <email>cdean@iacthealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Mukesh Kumar, MD</last_name>
      <email>mkumar@iacthealth.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cancer Care Specialists of Central Illinois</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jo Ellyn Curran</last_name>
      <email>jcurran@dmhhs.org</email>
    </contact>
    <contact_backup>
      <last_name>Dianna Richardson</last_name>
      <email>drichardson@dmhhs.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>James M Stockman Cancer Institute</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hema DiMaggio</last_name>
      <email>hdimaggio@fmh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Holy Cross Hospital Health Center</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lyudmila Kalnitskaya</last_name>
      <email>kalnitsl@holycrosshealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lahey Clinical Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Stagno-Scotto</last_name>
      <email>charles.a.stagno-scotto@lahey.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital Springfield</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrianna Moore</last_name>
      <email>adrianna.moore@mercy.net</email>
    </contact>
    <contact_backup>
      <last_name>Pearlena Hamlet</last_name>
      <email>pearlena.hamlet@mercy.net</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Saint Francis Cancer Treatment Center</name>
      <address>
        <city>Grand Island</city>
        <state>Nebraska</state>
        <zip>68803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Einspahr</last_name>
      <email>seinspahr@sfmc-gi.org</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Scott</last_name>
      <email>jscott@sfmc-gi.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jasmine Miller</last_name>
      <email>jasmine_miller@med.unc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Charlotte Dunn</last_name>
      <email>charlotte_dunn@med.unc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Oncology Specialists of Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joe Howe</last_name>
      <email>joe.howe@djlresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Lauren Jordan</last_name>
      <email>lauren.jordan@djlresearch.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UPMC Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Cieply</last_name>
      <email>cieplysl2@upmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah Health Care - Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Contantz</last_name>
      <email>Elizabeth.Constantz@hci.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Susan Clement</last_name>
      <email>Susan.Clement@hci.utah.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Clinique Saint-Pierre</name>
      <address>
        <city>Ottignies</city>
        <state>Brabant Wallon</state>
        <zip>1340</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Vanbellinghen</last_name>
      <email>isabelle.vanbellinghen@cspo.be</email>
    </contact>
    <contact_backup>
      <last_name>Martine Gerard</last_name>
      <email>martine.gerard@cspo.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Ardenne - Clinique du Sein</name>
      <address>
        <city>Libramont</city>
        <state>Luxembourg</state>
        <zip>6800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Celine Louis</last_name>
      <email>celine.louis@vivalia.be</email>
    </contact>
    <contact_backup>
      <last_name>Nathalie Antoine</last_name>
      <email>nathalie.antoine@vivalia.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuis Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mieke Verrecas</last_name>
      <email>mieke.verrecas@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Ellen Reynders</last_name>
      <email>ellen.reynders@uzleuven.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU UCL NAMUR - Sainte Elisabeth</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Crasson</last_name>
      <email>dominique.crasson@cmsenamur.be</email>
    </contact>
    <contact_backup>
      <last_name>Caroline Yague</last_name>
      <email>caroline.yague@cmsenamur.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari General de Catalunya</name>
      <address>
        <city>Sant Cugat Del Vallès</city>
        <state>Barcelona</state>
        <zip>08190</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georgina Simo</last_name>
      <email>gsimo@oncorosell.com</email>
    </contact>
    <contact_backup>
      <last_name>Teresa Alonso</last_name>
      <email>talonso@oncorosell.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Girona Doctor Josep Trueta</name>
      <address>
        <city>Gerona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Begona Martin</last_name>
      <email>bmartin@iconcologia.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaén</name>
      <address>
        <city>Jaén</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Fernandez</last_name>
      <email>musikfn@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Capilla De La Torre</last_name>
      <email>ctorrec@yahoo.es</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario La Coruña</name>
      <address>
        <city>La Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Belen Lopez</last_name>
      <email>belen.lopez.cortabitarte@sergas.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruben Tejero</last_name>
      <email>eoncolleida@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Fernandez Gonzalez</last_name>
      <email>sarafergon1@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ana Ruiz</last_name>
      <email>aruizbo.hgugm@yahoo.es</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón Y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adriana Hernanz Alvarez</last_name>
      <email>adriana.hernanz@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Estefania Menendez</last_name>
      <email>estefania.menpe@salud.madrid.org</email>
    </contact>
    <contact_backup>
      <last_name>Sandra Merino Avila</last_name>
      <email>sandra.merino@salud.madrid.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yolanda Alvarez</last_name>
      <email>yolandalapaz@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elsa Biondi</last_name>
      <email>dataclinico2@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Catoira</last_name>
      <email>catoira_isa@gva.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>59009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Concepción Velázquez</last_name>
      <email>cvelazquez.miguelservet@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Laura Rodriguez</last_name>
      <email>lrsastre70@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2017</study_first_submitted>
  <study_first_submitted_qc>August 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2017</study_first_posted>
  <last_update_submitted>April 27, 2018</last_update_submitted>
  <last_update_submitted_qc>April 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer, HER2 Negative, Hormone receptor positive, heregulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

